Fawzy AM, Bisson A, Bodin A, Herbert J, Lip GYH, Fauchier L
Active site residues C46 (oxidized), L48, Q81, and W136 are highlighted and shown as sticks
These medications are administered via subcutaneous injection, typically in the abdomen, thigh, or upper arm
Are these GLP-1 Booster capsules enough for managing obesity
The CMAJ guidance A guidance article published in the Canadian Medical Association Journal (CMAJ) on glucagon-like peptide-1 receptor agonists during pregnancy and lactation concluded that while the safety data is limited, the pharmacological properties of GLP-1 agonists (large molecular weight, poor oral bioavailability) suggest low theoretical risk during breastfeeding